Asensus Surgical, Inc. Schedules Fourth Quarter & Fiscal Year 2020 Financial & Operating Results Conference Call for March 11...
March 04 2021 - 6:55AM
Business Wire
Asensus Surgical, Inc. (NYSE American: TRXC) (formerly
TransEnterix, Inc.), a medical device company that is digitizing
the interface between the surgeon and patient to pioneer a new era
of Performance-Guided Surgery™, announced today that it plans to
release fourth quarter and fiscal year 2020 financial and operating
results after the market closes on Thursday, March 11, 2021. The
Company will host a conference call to discuss these results
starting at 4:30 p.m. ET the same day. The call will be
concurrently webcast.
To listen to the conference call on your telephone, please dial
1-855-327-6837 for domestic callers and 1-631-891-4304 for
international callers, and reference conference ID 10013234
approximately ten minutes prior to the start time. To access the
live audio webcast or archived recording, use the following link
https://ir.asensus.com/events-and-presentations. The replay will be
available on the Company’s website.
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the interface between the
surgeon and patient to pioneer a new era of Performance-Guided
Surgery by unlocking the Clinical Intelligence to enable
consistently superior outcomes and a new standard of surgery. This
builds upon the foundation of Digital Laparoscopy with the
Senhance® Surgical System powered by the Intelligent Surgical Unit™
(ISU™) to increase surgeon control and reduce surgical variability.
With the addition of machine vision, augmented intelligence, and
deep learning capabilities throughout the surgical experience, we
intend to holistically address the current clinical, cognitive and
economic shortcomings that drive surgical outcomes and value-based
healthcare. Learn more about Performance-Guided Surgery and Digital
Laparoscopy with the Senhance Surgical System here:
www.senhance.com. Now available for sale in the US, EU, Japan,
Russia, and select other countries. For a complete list of
indications for use, visit: www.senhance.com/indications. For more
information, visit www.asensus.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210304005118/en/
INVESTOR CONTACT: Mark Klausner or Mike Vallie,
443-213-0499 invest@asensus.com or MEDIA CONTACT: Kristin
Schaeffer CG Life kschaeffer@cglife.com
TransEnterix (AMEX:TRXC)
Historical Stock Chart
From Oct 2024 to Nov 2024
TransEnterix (AMEX:TRXC)
Historical Stock Chart
From Nov 2023 to Nov 2024